{
  "url": "https://struct.news/briefs/abbvies-profit-jumped-285-free-cash-flow-got-less-efficient",
  "title": "AbbVie’s profit jumped 285%. Free cash flow got less efficient",
  "summary": "Net income rose from $938.0M to $3.6B, while operating cash flow increased only 7% and capital spending rose.",
  "published_at": "2026-08-03T18:18:21.768970+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "AbbVie Inc.",
    "ticker": "ABBV",
    "cik": "1551152",
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-03",
    "accession": "0001551152-26-000026",
    "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-04",
    "url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/abbv-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "AbbVie valuation and cash generation",
      "label": "P/E",
      "value": 105.25561760530051,
      "display": "105.3x",
      "unit": "multiple",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001551152-26-000026",
        "filing_date": "2026-08-03"
      }
    },
    {
      "group": "AbbVie valuation and cash generation",
      "label": "Cash-flow yield",
      "value": 4.278228846530152,
      "display": "+4.3%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001551152-26-000026",
        "filing_date": "2026-08-03"
      }
    },
    {
      "group": "AbbVie valuation and cash generation",
      "label": "Market cap",
      "value": 444810240000,
      "display": "$444.8B",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "market_data",
        "label": "Observed market close",
        "as_of": "2026-07-31"
      }
    }
  ],
  "watch_next": [
    {
      "type": "demand",
      "statement": "Demand is diverging across products, with Elahere growing while Juvederm declines on weaker demand and unfavorable pricing.",
      "importance": "medium",
      "evidence": "Net revenues for Juvederm Collection decreased 7% for the three months and 5% for the six months ended June 30, 2026 primarily driven by decreased consumer demand and unfavorable pricing.",
      "source_date": "2026-08-03"
    }
  ],
  "related_tickers": [
    "ABBV"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}